English
Русский
中文
Português
日本語
Deutsch
한국어
Français
Italiano
TürkçePrestige Consumer Healthcare (PBH) Reports Q3 Earnings: What Key Metrics Have to Say
For the quarter ended December 2025, Prestige Consumer Healthcare (PBH) reported revenue of $283.44 million, down 2.4% over the same period last year. EPS came in at $1.14, compared to $1.22 in the year-ago quarter.
The reported revenue represents a surprise of +0.48% over the Zacks Consensus Estimate of $282.09 million. With the consensus EPS estimate being $1.16, the EPS surprise was -1.3%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Prestige Consumer Healthcare performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenues- OTC Healthcare- International: $47.75 million versus the three-analyst average estimate of $49.37 million. The reported number represents a year-over-year change of -7.1%. Revenues- OTC Healthcare- North American: $235.7 million compared to the $232.73 million average estimate based on three analysts. The reported number represents a change of -1.4% year over year. Gross profit- OTC Healthcare- North American: $130.7 million compared to the $132.2 million average estimate based on two analysts. Gross profit- OTC Healthcare- International: $26.67 million compared to the $26.62 million average estimate based on two analysts.View all Key Company Metrics for Prestige Consumer Healthcare here>>>
Shares of Prestige Consumer Healthcare have returned +6.9% over the past month versus the Zacks S&P 500 composite's +0.5% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Prestige Consumer Healthcare Inc. (PBH): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).